May 29, 2026 02:45PM Oculis Holding (OCS) Halted, News Pending

May 20, 2026 04:11PM Guggenheim Starts Oculis Holding AG (OCS) at Buy

May 13, 2026 07:50AM Oculis Holding AG (OCS) PT Raised to $47 at H.C. Wainwright

May 7, 2026 05:59AM Oculis receives FDA agreement on optic neuritis drug trial design

Apr 21, 2026 06:38AM H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)

Mar 5, 2026 06:51AM Oculis Holding AG (OCS) PT Raised to $44 at H.C. Wainwright

Mar 4, 2026 04:46PM Oculis Holding AG (OCS) PT Raised to $50 at Stifel

Jan 6, 2026 08:00AM Oculis receives FDA breakthrough therapy designation for optic neuritis drug

Dec 19, 2025 07:42AM Oculis Holding AG (OCS) PT Raised to $40 at Stifel; An 'Under-the-Radar Name'

Dec 19, 2025 05:16AM JPMorgan Starts Oculis Holding AG (OCS) at Overweight

Dec 3, 2025 07:18AM LifeSci Capital Starts Oculis Holding AG (OCS) at Outperform

Oct 7, 2025 06:39AM Oculis Holding AG (OCS) PT Raised to $36 at H.C. Wainwright

Oct 6, 2025 12:09PM Oculis Holding AG (OCS) PT Raised to $30 at BofA Securities

Aug 27, 2025 07:11AM Needham Starts Oculis Holding AG (OCS) at Buy

Aug 22, 2025 06:51AM Oculis Holding AG (OCS) PT Raised to $33 at H.C. Wainwright

Aug 22, 2025 05:33AM Stifel Reiterates Buy Rating on Oculis Holding AG (OCS)

Jun 5, 2025 04:43AM Oculis Holding AG (OCS) PT Raised to $50 at Leerink Partners

Apr 15, 2025 03:01PM Stifel Reiterates Buy Rating on Oculis Holding AG (OCS)

Apr 10, 2025 08:04AM Oculis Holding (OCS) Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Mar 13, 2025 06:41AM Oculis Holding AG (OCS) PT Lowered to $29 at H.C. Wainwright

Mar 12, 2025 09:18AM Stifel Reiterates Buy Rating on Oculis Holding AG (OCS)

Jan 7, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)

Jan 6, 2025 02:12PM Stifel Reiterates Buy Rating on Oculis Holding AG (OCS), PT $35

Oct 21, 2024 05:56AM Oculis (OCS) Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

Oct 2, 2024 06:13AM Oculis Holding (OCS) Appoints Daniel S. Char as Chief Legal Officer

Sep 5, 2024 05:41AM Leerink Partners Reiterates Outperform Rating on Oculis Holding AG (OCS)

Aug 28, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)

Aug 15, 2024 08:01AM Oculis Holding (OCS) Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

Jun 11, 2024 06:42AM Oculis Holding AG (OCS) PT Raised to $30 at H.C. Wainwright

Jun 11, 2024 06:36AM Oculis Holding AG (OCS) PT Raised to $37 at Baird

Jun 11, 2024 05:24AM Oculis Holding AG (OCS) PT Lowered to $20 at BofA Securities

Jun 10, 2024 04:30AM Oculis Holding (OCS) Reports Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab